| Ms Elizabeth Maccharles Barnaby, OTR-L, CHT | |
|
4015 Lake Otis Parkway, Suite 200, Anchorage, AK 99508 | |
| (907) 563-8318 | |
| Not Available |
| Full Name | Ms Elizabeth Maccharles Barnaby |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapy |
| Experience | 24 Years |
| Location | 4015 Lake Otis Parkway, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407923675 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 1421 (New Hampshire) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alaska Hand Rehabilitation Inc | 4284713231 | 7 |
News Archive
Scientists at Trinity College Dublin have uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases.
Shortages of prescription drugs are leaving a growing number of patients waiting for life-saving medicines. Federal officials say the number of prescriptions in short supply tripled from 2005 to 2010. Limited supplies of some drugs have sent prices soaring 1,000 times above normal.
Proteins in fluids bathing the brain are essential for building the brain, discover scientists in a report published March 10 in the journal Neuron. The finding promises to advance research related to neurological disease, cancer and stem cells.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the website of the U.S. Food and Drug Administration (FDA) indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Silenor® (doxepin) 3 mg and 6 mg was submitted on September 16, 2010.
Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.
› Verified 9 days ago
| Provider Name | Alaska Hand Rehabilitation Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1881730653 PECOS PAC ID: 4284713231 Enrollment ID: O20080502000252 |
News Archive
Scientists at Trinity College Dublin have uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases.
Shortages of prescription drugs are leaving a growing number of patients waiting for life-saving medicines. Federal officials say the number of prescriptions in short supply tripled from 2005 to 2010. Limited supplies of some drugs have sent prices soaring 1,000 times above normal.
Proteins in fluids bathing the brain are essential for building the brain, discover scientists in a report published March 10 in the journal Neuron. The finding promises to advance research related to neurological disease, cancer and stem cells.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the website of the U.S. Food and Drug Administration (FDA) indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Silenor® (doxepin) 3 mg and 6 mg was submitted on September 16, 2010.
Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Elizabeth Maccharles Barnaby, OTR-L, CHT 4015 Lake Otis Parkway, Suite 200, Anchorage, AK 99508 Ph: (907) 563-8318 | Ms Elizabeth Maccharles Barnaby, OTR-L, CHT 4015 Lake Otis Parkway, Suite 200, Anchorage, AK 99508 Ph: (907) 563-8318 |
News Archive
Scientists at Trinity College Dublin have uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases.
Shortages of prescription drugs are leaving a growing number of patients waiting for life-saving medicines. Federal officials say the number of prescriptions in short supply tripled from 2005 to 2010. Limited supplies of some drugs have sent prices soaring 1,000 times above normal.
Proteins in fluids bathing the brain are essential for building the brain, discover scientists in a report published March 10 in the journal Neuron. The finding promises to advance research related to neurological disease, cancer and stem cells.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the website of the U.S. Food and Drug Administration (FDA) indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Silenor® (doxepin) 3 mg and 6 mg was submitted on September 16, 2010.
Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.
› Verified 9 days ago
Paige N Thorne, MOTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 3831 Piper St Ste 220, Anchorage, AK 99508 Phone: 760-936-9766 | |
Forget Me Not Ot Llc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1048 W International Airport Rd, Suite 103, Anchorage, AK 99518 Phone: 907-317-5545 Fax: 907-865-2499 | |
Eva Cress Lyons, OTD Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 3801 Lake Otis Pkwy, Anchorage, AK 99508 Phone: 907-562-2277 | |
Mrs. Stacey Marie Lord, OTR L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8200 Homer Dr Ste F, Anchorage, AK 99518 Phone: 907-345-0050 Fax: 907-344-5103 | |
Ms. Tamara Dawn Moore, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 600 W 41st Ave Ste 103, Anchorage, AK 99503 Phone: 907-306-1728 Fax: 907-334-9320 | |
Marie Koleka Swanson, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 8200 Homer Dr Ste F, Anchorage, AK 99518 Phone: 907-345-0050 Fax: 907-344-5103 | |
Alexa Hanley, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 9100 Centennial Cir, Anchorage, AK 99504 Phone: 907-333-8100 |